Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > A concern?

<< Previous

Bullboard Posts

Next >>

Comment by SABBOBCATon Oct 30, 2022 11:20pm

118 Views

Post# 35059088

RE:A concern?

This would be the nail in the coffin for me. I would sell everything and call it a day.

Management says they have a strong hand then goes and dilutes at $2... no thanks.

If they cant make it to a poit where they can announce P1 results after the ONO, refinancing the debt, and having two revenue generating products then there is a HUGE problem.

Even if they had a strong hand this would indicate to me they dont know what they are doing. Even the right tool in the wrong hands can cause more problems than it fixes.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Sept. 27, 2024)